Yarrow Bioscience Launches Underwritten Public Offering to Fund Pipeline
YARW has more than doubled off its 52-week low of $14.165.
Summary
Yarrow Bioscience announced an underwritten public offering of common stock or pre-funded warrants, with an option for underwriters to purchase up to an additional 15% of shares. The offering size and pricing are not yet disclosed, but the company intends to use proceeds for R&D and general corporate purposes. This follows the recent merger with VYNE Therapeutics and the initiation of a Phase 2a/2b trial for YB-101. The offering will dilute existing shareholders, and the lack of specific terms adds uncertainty. Jefferies, TD Cowen, and Guggenheim are joint book-running managers, with LifeSci Capital as lead manager. The shelf registration was declared effective on August 19, 2026.
At the time of this announcement, YARW was trading at $28.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $75.9M. The 52-week trading range was $14.17 to $46.95. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.